908 Devices FY2024 EPS Forecast Lifted by William Blair

908 Devices Inc. (NASDAQ:MASS) – Research analysts at William Blair increased their FY2024 EPS estimates for shares of 908 Devices in a research note issued on Tuesday, November 12th. William Blair analyst M. Larew now anticipates that the company will earn ($1.18) per share for the year, up from their previous estimate of ($1.19). The consensus estimate for 908 Devices’ current full-year earnings is ($1.22) per share.

MASS has been the topic of several other research reports. Stifel Nicolaus cut their price objective on 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday. Leerink Partnrs downgraded 908 Devices from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Leerink Partners reissued a “market perform” rating and set a $4.00 price target (down previously from $12.00) on shares of 908 Devices in a research report on Wednesday.

908 Devices Stock Up 1.7 %

Shares of NASDAQ MASS opened at $2.38 on Thursday. 908 Devices has a 52-week low of $2.19 and a 52-week high of $12.51. The business’s 50 day moving average is $3.47 and its two-hundred day moving average is $4.70. The firm has a market cap of $82.49 million, a price-to-earnings ratio of -1.32 and a beta of 0.98.

Institutional Investors Weigh In On 908 Devices

Several large investors have recently bought and sold shares of the stock. Townsquare Capital LLC acquired a new position in shares of 908 Devices during the third quarter worth about $50,000. 49 Wealth Management LLC lifted its stake in 908 Devices by 16.2% in the third quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock worth $108,000 after acquiring an additional 4,343 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in 908 Devices by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after acquiring an additional 28,015 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of 908 Devices in the 3rd quarter valued at approximately $190,000. Finally, Drive Wealth Management LLC acquired a new stake in shares of 908 Devices in the 3rd quarter valued at $50,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.